Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: Update Bulletin [June 2015]

Product Code:
Release Date:
June 2015

Gain new KOL insights on the latest events happening in Ulcerative colitis. Topics covered: Ozanimod’s oral formulation, early-stage Lycera compound, PML, IMO 9200, Bertilimumab, biosimilar infliximab in UC

Highlights from this event update bulletin

  • How do KOLs view recently reported Phase II data of Receptos' ozanimod?
  • How do KOLs perceive Lycera's LYC 30937?Will Ajinomoto's/Kissei's AJM 300, an oral integrin antagonist, be a success?
  • How will Immune Pharmaceuticals' bertilimumab be used if approved?
  • Why is there optimism for Idera's Toll-like receptor antagonist, IMO 9200?
  • How do KOLs view biosimilar infliximab for the treatment of UC and why?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved